Valneva SE (VALN)
| Previous close | 19.96 |
| Open | 19.35 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's range | 19.35 - 20.16 |
| 52-week range | 13.71 - 67.84 |
| Volume | |
| Avg. volume | 25,566 |
| Market cap | 1.158B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.49 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 39.68 |
- Globe Newswire
VALNEVA - Declaration of shares and voting rights - July 31, 2022
VALNEVA Declaration of shares and voting rights July 31, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: August 4, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change was
- Globe Newswire
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine
Saint-Herblain (France), August 1, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreement (APA)1 with the European Commission (EC), following expiration of the Member States’ opt-out period, as announced by the Company on July 20, 20222. Under this amendment, the Member States’ purchases of VLA2001, Valneva’s inactivated whole-virus COVID-19 vaccine, consist of 1.25 million doses of VLA2001
- Globe Newswire
European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine
European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Saint-Herblain (France), July 20, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the European Commission (EC) has approved an amendment to the Advance Purchase Agreement (APA) it signed in November 20211 for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001. The amendment will be signed after a mandatory five-day period duri
